Scholarlink

Background <p>Coronary artery bypass grafting (CABG) is a common intervention for coronary artery disease, but postoperative myocardial microcirculation and recovery remain challenging. This study aimed to evaluate the effects of rosuvastatin calcium on myocardial microcirculation and postoperative outcomes in CABG patients.</p> Methods <p>This retrospective cohort study included 216 patients who underwent CABG between February 2020 and February 2024. Participants were divided into a conventional treatment group (<i>n</i> = 111) and a rosuvastatin group (<i>n</i> = 105) receiving additional rosuvastatin calcium (10&#xa0;mg/day) from 7 days pre-surgery to 28 days post-surgery. Cardiac echocardiography, blood tests (inflammatory markers, lipids, and cardiac enzymes), and New York Heart Association (NYHA) functional classification were assessed preoperatively and 8 weeks postoperatively. Postoperative complications and mortality were monitored during a one-year follow-up.</p> Results <p>The rosuvastatin group showed significantly improved left ventricular remodeling, with reduced left ventricular end-diastolic diameter (LVEDD, <i>P</i> = 0.022), Left Ventricular Septal Thickness (LVST, <i>P</i> = 0.048), and Left Ventricular Posterior Wall Thickness (LVPWT, <i>P</i> = 0.019). Enhanced systolic function was evidenced by higher LVEF (<i>P</i> &lt; 0.001) and Left Ventricular Fractional Shortening (LVFS, <i>P</i> &lt; 0.001). Myocardial microcirculation parameters including Left Acceleration Time (AT), Pulsatility Index (PI), and Aortic Pre-Ejection Period (APT) also improved (all <i>P</i> &lt; 0.05). Additionally, the rosuvastatin group had lower postoperative creatine kinase MB isoenzyme (CK-MB, <i>P</i> = 0.012), higher High-Density Lipoprotein Cholesterol (HDL-C, <i>P</i> = 0.003), and reduced incidence of atrial fibrillation (<i>P</i> = 0.007) and all-cause mortality (<i>P</i> = 0.026).</p> Conclusion <p>Rosuvastatin calcium administration significantly improves myocardial microcirculation, cardiac function, and postoperative recovery in CABG patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rosuvastatin calcium administration and its impact on myocardial microcirculation and postoperative recovery in patients undergoing coronary artery bypass grafting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Xizheng Wang,
  • Hongwei Qi,
  • Jiangang Zhao,
  • Nan Chen,
  • Biao Yuan

摘要

Background

Coronary artery bypass grafting (CABG) is a common intervention for coronary artery disease, but postoperative myocardial microcirculation and recovery remain challenging. This study aimed to evaluate the effects of rosuvastatin calcium on myocardial microcirculation and postoperative outcomes in CABG patients.

Methods

This retrospective cohort study included 216 patients who underwent CABG between February 2020 and February 2024. Participants were divided into a conventional treatment group (n = 111) and a rosuvastatin group (n = 105) receiving additional rosuvastatin calcium (10 mg/day) from 7 days pre-surgery to 28 days post-surgery. Cardiac echocardiography, blood tests (inflammatory markers, lipids, and cardiac enzymes), and New York Heart Association (NYHA) functional classification were assessed preoperatively and 8 weeks postoperatively. Postoperative complications and mortality were monitored during a one-year follow-up.

Results

The rosuvastatin group showed significantly improved left ventricular remodeling, with reduced left ventricular end-diastolic diameter (LVEDD, P = 0.022), Left Ventricular Septal Thickness (LVST, P = 0.048), and Left Ventricular Posterior Wall Thickness (LVPWT, P = 0.019). Enhanced systolic function was evidenced by higher LVEF (P < 0.001) and Left Ventricular Fractional Shortening (LVFS, P < 0.001). Myocardial microcirculation parameters including Left Acceleration Time (AT), Pulsatility Index (PI), and Aortic Pre-Ejection Period (APT) also improved (all P < 0.05). Additionally, the rosuvastatin group had lower postoperative creatine kinase MB isoenzyme (CK-MB, P = 0.012), higher High-Density Lipoprotein Cholesterol (HDL-C, P = 0.003), and reduced incidence of atrial fibrillation (P = 0.007) and all-cause mortality (P = 0.026).

Conclusion

Rosuvastatin calcium administration significantly improves myocardial microcirculation, cardiac function, and postoperative recovery in CABG patients.